Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could adding a second diabetes drug early save lives?

NCT ID NCT07465926

Knowledge-focused Sponsor: Chung Shan Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study analyzed health records from over 450,000 adults with obesity and type 2 diabetes to see if adding a GLP-1 or SGLT2 drug early improves survival and kidney health. Researchers compared those who added the other drug class within 90 days to those who added a different drug or no early add-on. The goal was to see if early combination therapy reduces death and heart or kidney problems over three years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist and SGLT2 inhibitor
What this could lead to
If results are positive, this could suggest that adding a second drug early improves survival and kidney health in people with obesity and type 2 diabetes.
What could go wrong
This is an observational study using existing records, not a controlled trial. It can show links but cannot prove cause and effect. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

451,036 people

The number who actually took part.

Started

Jan 2017

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults (≥20 years) with obesity, type 2 diabetes, and cardiovascular-kidney-metabolic stage 2-3 identified from routinely collected electronic health record data in the TriNetX US Collaborative Network. Participants initiated a GLP-1 receptor agonist or an SGLT2 inhibitor and were classified according to early add-on treatment strategies.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 20 years or older. * Obesity, defined by body mass index (BMI) 27 kg/m2 or greater. * Type 2 diabetes mellitus, defined using electronic health record data, including diagnosis codes and/or hemoglobin A1c 6.5% or greater. * Met cardiovascular-kidney-metabolic (CKM) stage 2-3 criteria at baseline. * Initiated a GLP-1 receptor agonist or an SGLT2 inhibitor as background therapy. * Had treatment strategy classification based on early add-on initiation within 90 days after background therapy initiation, or no early add-on with index at the 90-day landmark. Exclusion Criteria: * Prior use of GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas within 6 months before cohort entry. * Major cardiovascular disease or revascularization within 12 months before cohort entry. * Advanced kidney disease within 12 months before cohort entry, including end-stage kidney disease, dialysis, or estimated glomerular filtration rate less than 15 mL/min/1.73 m2. * Major cardiovascular or renal events within 6 months before index. * Any history of non-type 2 diabetes, HIV infection, bariatric surgery, or solid-organ transplantation. * Missing critical baseline covariates.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease risk factor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular-kidney-metabolic syndrome impaired renal function disease kidney disorder Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease risk factor Cardiovascular-kidney-metabolic syndrome Kidney disease Obesity & overweight Type 2 diabetes

More trials for these conditions

Other studies related to the condition(s) this trial covers.